Danish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Targeting the Gut Microbiome for Prader-Willi Syndrome Treatment

Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Linket gemmes på udklipsholderen
StatusAfsluttet
Sponsorer
Fundació Sant Joan de Déu

Nøgleord

Abstrakt

The gut microbiome has recently emerged as a major contributor to obesity, systemic inflammation, and metabolic disease. Furthermore, intestinal bacteria are crucial players in the gut-brain axis, regulating a broad range of central nervous system processes, from satiety mechanisms to anxiety and social behavior. Thus, targeting the microbiome is being actively investigated as a therapeutic strategy for a wide array of diseases, including obesity, anxiety, depression, and autism. Among all intestinal bacteria, Bifidobacterium animalis spp. lactis (BAL) has shown promise for obesity treatment in experimental animal models and human subjects, improving body composition and metabolic health, and reducing energy intake. Moreover, tryptophan metabolism, a crucial regulator of satiety mechanisms and anxiety, is a main target of BAL. Given that clinical manifestations of Prader-Willi syndrome (PWS) include hyperphagia, anxiety, altered body composition, and metabolic dysregulation, the aforementioned effects of BAL might prove highly beneficial for children with PWS. Here, the investigators will test this hypothesis by performing a randomized double-blinded placebo-controlled crossover clinical study to assess the effects of BAL supplementation on an array of clinical manifestations of PWS. Children with PWS will undergo a 3-month placebo/probiotic treatment period, a 3-month washout period, followed by a 3-month probiotic/placebo supplementation. Anthropometric, biochemical, and psychological data as well as biological samples will be obtained at the beginning of the study, and after each of the study periods, with a total of four time-points. Specifically, the investigators will determine body composition by DXA analysis; metabolic health by assessing glucose and lipid metabolic parameters as well as circulating hormonal and cytokine levels; thermoregulation by non-invasive thermal imaging; and hyperphagia and emotional and behavioral problems by applying parental-rated validated questionnaires.

Datoer

Sidst bekræftet: 02/29/2020
Først indsendt: 05/01/2018
Anslået tilmelding indsendt: 06/05/2018
Først indsendt: 06/06/2018
Sidste opdatering indsendt: 03/03/2020
Sidste opdatering indsendt: 03/04/2020
Faktisk startdato for undersøgelsen: 12/31/2017
Anslået primær afslutningsdato: 01/30/2019
Anslået afslutningsdato for undersøgelsen: 01/30/2019

Tilstand eller sygdom

Prader-Willi Syndrome

Intervention / behandling

Dietary Supplement: Placebo

Dietary Supplement: Probiotic

Fase

-

Armgrupper

ArmIntervention / behandling
Placebo Comparator: Placebo
Dietary Supplement: Placebo
Intervention with a daily dose of placebo
Experimental: Probiotic
Dietary Supplement: Probiotic
Intervention with a daily dose of probiotic

Kriterier for støtteberettigelse

Alder berettiget til undersøgelse 2 Years Til 2 Years
Køn, der er berettiget til undersøgelseAll
Accepterer sunde frivilligeJa
Kriterier

Inclusion Criteria:

- Diagnosed with Prader-Willi Syndrome with genetic confirmation

- On a stable diet and medication regimen for at least the last two months before enrollment

Exclusion Criteria:

- Current enrollment in or discontinuation within the last 30 days from a clinical trial

- Presence of other medical problems that would preclude study participation

- Patients with a history of bariatric surgery

- Unsuitable for inclusion in the study in the opinion of the investigator

Resultat

Primære resultatforanstaltninger

1. Change in percent body fat [3 months]

Measured by DXA scan

Sekundære resultatforanstaltninger

1. Change in lipid profile (triglyceride, cholesterol) [3 months]

Blood test after overnight fasting

2. Change in glucose metabolic parameters (glucose, insulin, HbA1c) [3 months]

Blood test after overnight fasting

3. Change in circulating cytokine levels [3 months]

Quantified in plasma samples

4. Change in hyperphagia [3 months]

Measured by validated questionnaire (HQ-CT)

5. Change in thermoregulation [3 months]

Measured by thermal imaging

Andre resultater

1. Change in plasma metabolome [3 months]

Liquid chromatography coupled to mass spectrometry will be used to obtain a comprehensive metabolic profile of plasma samples

2. Change in urine metabolome [3 months]

Liquid chromatography coupled to mass spectrometry will be used to obtain a comprehensive metabolic profile of urine samples

3. Change in intestinal microbiome [3 months]

DNA isolated from fecal samples will be analyzed by sequencing.

Deltag i vores
facebook-side

Den mest komplette database med medicinske urter understøttet af videnskab

  • Arbejder på 55 sprog
  • Urtekurer, der understøttes af videnskab
  • Urtegenkendelse ved billede
  • Interaktivt GPS-kort - tag urter på stedet (kommer snart)
  • Læs videnskabelige publikationer relateret til din søgning
  • Søg medicinske urter efter deres virkninger
  • Organiser dine interesser og hold dig opdateret med nyhedsundersøgelser, kliniske forsøg og patenter

Skriv et symptom eller en sygdom, og læs om urter, der kan hjælpe, skriv en urt og se sygdomme og symptomer, den bruges mod.
* Al information er baseret på offentliggjort videnskabelig forskning

Google Play badgeApp Store badge